221 related articles for article (PubMed ID: 22634023)
1. Molecular tools for companion diagnostics.
Zieba A; Grannas K; Söderberg O; Gullberg M; Nilsson M; Landegren U
N Biotechnol; 2012 Sep; 29(6):634-40. PubMed ID: 22634023
[TBL] [Abstract][Full Text] [Related]
2. The role of companion diagnostics in the development and use of mutation-targeted cancer therapies.
Papadopoulos N; Kinzler KW; Vogelstein B
Nat Biotechnol; 2006 Aug; 24(8):985-95. PubMed ID: 16900147
[TBL] [Abstract][Full Text] [Related]
3. Companion diagnostics: the key to personalized medicine. Foreword.
Jørgensen JT
Expert Rev Mol Diagn; 2015 Feb; 15(2):153-6. PubMed ID: 25597758
[TBL] [Abstract][Full Text] [Related]
4. Do companion diagnostics make economic sense for drug developers?
Agarwal A
N Biotechnol; 2012 Sep; 29(6):695-708. PubMed ID: 22575210
[TBL] [Abstract][Full Text] [Related]
5. Best practices for companion diagnostic and therapeutic development: translating between the stakeholders.
Love D; Stratton E; Stocum M
N Biotechnol; 2012 Sep; 29(6):689-94. PubMed ID: 22743138
[TBL] [Abstract][Full Text] [Related]
6. The potential of circulating nucleic acids as components of companion diagnostics for predicting and monitoring chemotherapy response.
Schwarzenbach H
Expert Rev Mol Diagn; 2015 Feb; 15(2):267-75. PubMed ID: 25382372
[TBL] [Abstract][Full Text] [Related]
7. [Companion diagnostics: significances and issues in its clinical application].
Miyachi H
Rinsho Byori; 2011 Jun; 59(6):602-9. PubMed ID: 21815484
[TBL] [Abstract][Full Text] [Related]
8. The evolving potential of companion diagnostics.
Khoury JD
Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
[TBL] [Abstract][Full Text] [Related]
9. Predictive markers in early research and companion diagnostic developments in oncology.
Pickl M; Ruge E; Venturi M
N Biotechnol; 2012 Sep; 29(6):651-5. PubMed ID: 22484859
[TBL] [Abstract][Full Text] [Related]
10. Isolation of rare circulating tumor cells in cancer patients: technical aspects and clinical implications.
Danova M; Torchio M; Mazzini G
Expert Rev Mol Diagn; 2011 Jun; 11(5):473-85. PubMed ID: 21707456
[TBL] [Abstract][Full Text] [Related]
11. Improving the power of diagnostics in the era of targeted therapy and personalized healthcare.
Walk EE
Curr Opin Drug Discov Devel; 2010 Mar; 13(2):226-34. PubMed ID: 20205056
[TBL] [Abstract][Full Text] [Related]
12. Fujirebio Diagnostics to develop cancer diagnostics.
Expert Rev Mol Diagn; 2002 Mar; 2(2):93. PubMed ID: 11962340
[No Abstract] [Full Text] [Related]
13. Molecular diagnostics: a new frontier in cancer prevention.
Wagner PD; Maruvada P; Srivastava S
Expert Rev Mol Diagn; 2004 Jul; 4(4):503-11. PubMed ID: 15225098
[TBL] [Abstract][Full Text] [Related]
14. Companion and complementary diagnostics: an important treatment decision tool in precision medicine.
Jørgensen JT
Expert Rev Mol Diagn; 2020 Jun; 20(6):557-559. PubMed ID: 32342707
[No Abstract] [Full Text] [Related]
15. Companion diagnostics and molecular imaging-enhanced approaches for oncology clinical trials.
Van Heertum RL; Scarimbolo R; Ford R; Berdougo E; O'Neal M
Drug Des Devel Ther; 2015; 9():5215-23. PubMed ID: 26392755
[TBL] [Abstract][Full Text] [Related]
16. From morphologic to molecular: established and emerging molecular diagnostics for breast carcinoma.
Portier BP; Gruver AM; Huba MA; Minca EC; Cheah AL; Wang Z; Tubbs RR
N Biotechnol; 2012 Sep; 29(6):665-81. PubMed ID: 22504737
[TBL] [Abstract][Full Text] [Related]
17. Special report: companion diagnostics--example of BRAF gene mutation testing to select patients with melanoma for treatment with BRAF kinase inhibitors.
Technol Eval Cent Assess Program Exec Summ; 2011 Nov; 26(7):1-5. PubMed ID: 22724160
[No Abstract] [Full Text] [Related]
18. [Health care expenditures linked to the use of targeted therapies and diagnostic tests for cancer patients].
Marino P; Bertucci F; Gonçalves A; Seror V
Med Sci (Paris); 2012 Mar; 28 Spec No 1():19-23. PubMed ID: 22494652
[TBL] [Abstract][Full Text] [Related]
19. [Current situation and challenges in companion diagnostics development].
Nishida M
Gan To Kagaku Ryoho; 2014 Dec; 41(13):2529-34. PubMed ID: 25596043
[TBL] [Abstract][Full Text] [Related]
20. US FDA perspective on challenges in co-developing in vitro companion diagnostics and targeted cancer therapeutics.
Philip R; Carrington L; Chan M
Bioanalysis; 2011 Feb; 3(4):383-9. PubMed ID: 21338257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
